Vivo Opportunity entities disclose 9.99% Pasithea Therapeutics (KTTA) holdings via warrants and stock
Vivo Opportunity entities, including Vivo Opportunity Fund Holdings, L.P. and Vivo Opportunity Cayman Fund, L.P., have reported beneficial ownership of 9.99% of Pasithea Therapeutics (KTTA) common stock. These holdings comprise a mix of common shares and pre-funded warrants, which include provisions to prevent ownership …